Condition: Non-hodgkin's Lymphoma · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT
This description comes directly from the study's public registry record.
Sa Xiao, PHD · +86-15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Harbin First Hospital | Haerbin, Heilongjing, China | Recruiting |
| Qingdao Central Hospital | Qingdao, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05623982